Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Anne Dornhorst. (2005) Comment on Post-marketing surveillance: a UK/European perspective. Current Medical Research and Opinion 21:9, pages 1401-1402.
Read now
Read now
Articles from other publishers (33)
Carlo Combi, Julio C. Facelli, Peter Haddawy, John H. Holmes, Sabine Koch, Hongfang Liu, Jochen Meyer, Mor Peleg, Giuseppe Pozzi, Gregor Stiglic, Pierangelo Veltri & Christopher C. Yang. (2023) The IHI Rochester Report 2022 on Healthcare Informatics Research: Resuming After the CoViD-19. Journal of Healthcare Informatics Research 7:2, pages 169-202.
Crossref
Crossref
Salim Faruk Bashir, Shivani Meena & Gaurav Kumar. 2023. Current Trends in the Identification and Development of Antimicrobial Agents. Current Trends in the Identification and Development of Antimicrobial Agents
68
104
.
Emily M Schorr & Peter A Calabresi. (2022) Generic MS medications: Reducing costs without compromising safety. Multiple Sclerosis Journal 28:14, pages 2157-2159.
Crossref
Crossref
Nikita Tapkir, Fatema Soni, Amit Kumar Sahu, Tarang Jadav, Rakesh K. Tekade & Pinaki Sengupta. (2021) A Comprehensive Review on Assessment and Key Control Strategies for Impurities in Drug Development with a Special Emphasis on Post-marketing Surveillance. Journal of Pharmaceutical Innovation 17:4, pages 1510-1529.
Crossref
Crossref
Ramesh Nadarajah & Chris P Gale. (2019) Profiling the cohort profile. European Heart Journal - Quality of Care and Clinical Outcomes 5:3, pages 185-186.
Crossref
Crossref
Nikhil Raj, Swapnil Fernandes, Narayana R. Charyulu, Akhilesh Dubey, Ravi G. S. & Srinivas Hebbar. (2019) Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Therapeutic Advances in Drug Safety 10, pages 204209861986541.
Crossref
Crossref
Mary Wiktorowicz, Kathy Moscou & Joel Lexchin. (2018) Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence. Globalization and Health 14:1.
Crossref
Crossref
Robyn Tamblyn, Nadyne Girard, William G. Dixon, Jennifer Haas, David W. Bates, Thérèse Sheppard, Tewodros Eguale, David Buckeridge, Michal Abrahamowicz & Alan Forster. (2016) Pharmacosurveillance without borders: electronic health records in different countries can be used to address important methodological issues in estimating the risk of adverse events. Journal of Clinical Epidemiology 77, pages 101-111.
Crossref
Crossref
Claude Negrier, Sophie Voisin, Fariba Baghaei, Robert Numerof, Aaron Novack, Jennifer E. Doralt, Vadim Romanov & Alessandro Gringeri. (2016) Global Post-Authorization Safety Surveillance Study. Blood Coagulation & Fibrinolysis 27:5, pages 551-556.
Crossref
Crossref
Stephen P. Glasser, Elizabeth Delzell & Maribel Salas. 2014. Essentials of Clinical Research. Essentials of Clinical Research
91
116
.
Khaled El Emam, Saeed Samet, Luk Arbuckle, Robyn Tamblyn, Craig Earle & Murat Kantarcioglu. (2013) A secure distributed logistic regression protocol for the detection of rare adverse drug events. Journal of the American Medical Informatics Association 20:3, pages 453-461.
Crossref
Crossref
Mary Wiktorowicz, Joel Lexchin & Kathy Moscou. (2012) Pharmacovigilance in Europe and North America: Divergent approaches. Social Science & Medicine 75:1, pages 165-170.
Crossref
Crossref
Abdunoor M Kabanywanyi, Nathan Mulure, Christopher Migoha, Aggrey Malila, Christian Lengeler, Raymond Schlienger & Blaise Genton. (2010) Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting. Malaria Journal 9:1.
Crossref
Crossref
Hans Petri, Debra Maldonato & Noah Jamie Robinson. (2010) Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskeletal Disorders 11:1.
Crossref
Crossref
Saied Khader, Waleed AbdelFattah, Abdulqawi Almansari & Nabil K. Elnnagar. (2010) Safety and efficacy of switching to biphasic insulin aspart 30/70 (BIAsp 30) under the routine diabetic care in patients with type 2 diabetes: The IMPROVE™ observational study in the Gulf region. International Journal of Diabetes Mellitus 2:2, pages 110-113.
Crossref
Crossref
S. M. Breathnach. 2010. Rook's Textbook of Dermatology. Rook's Textbook of Dermatology
1
177
.
K. N. Woodward. 2009. Veterinary Pharmacovigilance. Veterinary Pharmacovigilance
423
452
.
J. Gumprecht, M. Benroubi, V. Borzi, R. Kawamori, J. Shaban, S. Shah, M. Shestakova, Y. Wenying, R. Ligthelm & P. Valensi. (2009)
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix
®
30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE
™
observational study
. International Journal of Clinical Practice 63:6, pages 966-972.
Crossref
Crossref
Robert J. Ligthelm. (2009) Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Primary Care Diabetes 3:2, pages 97-102.
Crossref
Crossref
Marina Shestakova, Ole Molskov Bech & Munther S. Momani. (2008) Study design and baseline characteristics of patients in the PRESENT study. Diabetes Research and Clinical Practice 81, pages S3-S9.
Crossref
Crossref
S. A. Schreiber. (2008) Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience. Diabetes, Obesity and Metabolism 10:s2, pages 24-34.
Crossref
Crossref
Catherine Baldridge. (2008) Which drug reactions should be reported?. Practice Nursing 19:4, pages 182-184.
Crossref
Crossref
Philippe R. Koninckx. (2008) Videoregistration of Surgery Should be Used as a Quality Control. Journal of Minimally Invasive Gynecology 15:2, pages 248-253.
Crossref
Crossref
Stephen P. Glasser, Elizabeth Delzell & Maribel Salas. 2008. Essentials of Clinical Research. Essentials of Clinical Research
73
91
.
Stephen P. Glasser, Maribel Salas & Elizabeth Delzell. (2013) Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self‐Reporting Systems. The Journal of Clinical Pharmacology 47:9, pages 1074-1086.
Crossref
Crossref
Samantha Hamer & Peter M. Haddad. (2018) Adverse effects of antipsychotics as outcome measures. British Journal of Psychiatry 191:S50, pages s64-s70.
Crossref
Crossref
Adam B. Mayerson. (2007) Levemir® Early Clinical Experience Case Series. Endocrinology and Metabolism Clinics of North America 36, pages 45-52.
Crossref
Crossref
L. F. Meneghini, K. H. Rosenberg, C. Koenen, M. J. Merilainen & H.-J. Lüddeke. (2007) Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes, Obesity and Metabolism 9:3, pages 418-427.
Crossref
Crossref
Peter M Haddad & Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. CNS Drugs 21:11, pages 911-936.
Crossref
Crossref
Robert J. Ligthelm, Vito Borzì, Janusz Gumprecht, Ryuzo Kawamori, Yang Wenying & Paul Valensi. (2007) Importance of Observational Studies in Clinical Practice. Clinical Therapeutics 29:6, pages 1284-1292.
Crossref
Crossref
Stephen P. Glasser. (2006) Antihypertensive safety and efficacy and physician and patient satisfaction: results from a phase 4 practice-based clinical experience trial with diltiazem LA. Advances in Therapy 23:2, pages 284-294.
Crossref
Crossref
Catherine Baldridge. (2005) Which drug reactions should be reported?. Practice Nursing 16:12, pages 584-589.
Crossref
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:11, pages i-xii.
Crossref
Crossref